Vudalimab is a humanized bispecific monoclonal antibody targeting both PD-1 and CTLA-4. Vudalimab inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.